Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASALT trial of tocilizumab with neoadjuvant chemoradiotherapy in esophageal adenocarcinoma
NL-OMON60701Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tocilizumab in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Pathological response by Mandard criteria. Started Jan 2021; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON60701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60701.